Maternal transfer of antibodies to the offspring after mice immunization with insect larvae-derived recombinant hepatitis E virus ORF-2 proteins

Virus Research

Volumn 158, Issue 1-2, 2011, Pages 28-32

  Jiménez de Oya, Nereida ^a   Alonso Padilla, Julio ^a,b   Blázquez, Ana Belén ^a   Escribano Romero, Estela ^a   Escribano, José M ^a   Saiz, Juan Carlos ^a  

^a INIA   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Insect biofactories; Passive immune transfer; Vaccine

Indexed keywords

AMINO ACID; ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MATERNAL ANTIBODY; RECOMBINANT OPEN READING FRAME 2 PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTHROPOD LARVA; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; FEMALE; HEPATITIS E VIRUS; HUMAN; IMMUNOGENICITY; LACTATION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PLACENTAL TRANSFER; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; TECHNOLOGY;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, VIRAL; BACULOVIRIDAE; BIOTECHNOLOGY; FEMALE; GENETIC VECTORS; HEPATITIS E VIRUS; IMMUNITY, MATERNALLY-ACQUIRED; INSECTS; MICE; MICE, INBRED C57BL; PREGNANCY; TECHNOLOGY, PHARMACEUTICAL; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

HEPATITIS E VIRUS; HEXAPODA; MUS;

EID: 79956335686     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.02.019     Document Type: Article

References (24)

1. Aggarwal R., Jameel S. Hepatitis E vaccine. Hepatol. Int. 2008, 2(3):308-315.
2. Dalton H.R., Bendall R., Ijaz S., Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect. Dis. 2008, 8:698-709.
3. Hasselquist D., Nilsson J.A. Maternal transfer of antibodies in vertebrates: trans-generational effects on offspring immunity. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2009, 364(1513):51-60.
4. Jiménez de Oya N., Galindo I., Escribano-Romero E., Blázquez A.B., Alonso-Padilla J., Halaihel N., Escribano J.M., Saiz J.C. Expression and immunoreactivities of hepatitis E virus genotype 3 open reading frame-2 (ORF-2) recombinant proteins expressed in insect cells. Food Environ. Virol. 2009, 1(1):77-84.
5. Jiménez de Oya N., Galindo I., Gironés O., Duizer E., Escribano J.M., Saiz J.C. Serological immunoassay for detection of hepatitis E virus on the basis of genotype 3 open reading frame 2 recombinant proteins produced in Trichoplusia ni larvae. J. Clin. Microbiol. 2009, 47(10):3276-3282.
6. Khuroo M.S., Kamili S. Aetiology, clinical course and outcome of sporadic acute liver viral hepatitis in pregnancy. J. Viral Hepat. 2003, 10(1):61-69.
7. Kost T.A., Condreay J.P., Jarvis D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 2005, 23(5):567-575.
8. Li T.C., Suzaki Y., Ami Y., Tsunemitsu H., Miyamura T., Takeda N. Mice are not susceptible to hepatitis E virus infection. J. Vet. Med. Sci. 2005, 70(12):1359-1362.
9. Li S.W., Zhang J., Li Y.M., Ou S.H., Huang G.Y., He Z.Q., Ge S.X., Xian Y.L., Pang S.Q., Ng M.H., Xia N.S. A bacterially expressed praticulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005, 23(22):2893-2901.
10. Li T.C., Yamakawa Y., Suzuki K., Tatsumi M., Razak M.A., Uchisa T., Takeda N., Myamura T. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J. Virol. 1997, 71(10):7207-7213.
11. Liu Y., DeCarolis N., Beck N. Protein production with recombinant baculoviruses in lepidopteran larvae. Methods Mol. Biol. 2007, 388:267-280.
12. Medin J.A., Hunt L., Gathy K., Evans R.K., Coleman M.S. Efficient, low-cost protein factories: expression of human adenosine deaminase in baculovirus-infected insect larvae. Proc. Natl. Acad. Sci. U.S.A. 1990, 87(7):2760-2764.
13. Meng X.J. Recent advances in hepatitis E virus. J. Viral Hepat. 2010, 17(3):153-161.
14. Meng J., Pillot J., Dai X., Fields H.A., Khudyakov K.E. Neutralization of different geographic strains of the hepatitis E virus with anti-hepatitis E virus-positive serum samples obtained from different sources. Virology 1998, 249(2):316-324.
15. Perez-Martin E., Gomez-Sebastian S., Argilaguet J.M., Sibila M., Fort M., Nofrarias M., Kurtz S., Escribano J.M., Segales J., Rodriguez F. Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae. Vaccine 2010, 28(11):2340-2349.
16. Pintó R., Saiz J.C. Human viruses in water. Perspectives in Medical Virology 2007, vol. 17:39-67. Elsevier, Amsterdam, The Netherlands.
17. Sharapov M.B., Favorov M.O., Yashina T.L., Brown M.S., Onischenko G.O., Margolis H.S., Chorba T.L. Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data. BMC Infect. Dis. 2009, 9:35-43.
18. Shrestha M.P., Scott R.M., Joshi D.M., Mammen M.P., Thapa G.B., Thapa N., Myint K.S., Fourneau M., Kuschner R.A., Shrestha S.K., David M.P., Seriwatana J., Vuaghn D.W., Safary A., Endy T.P., Innis B.L. Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 2007, 356(9):895-903.
19. Teshale E.H., Howard C.M., Grytdal S.P., Handzel T.R., Barry V., Kamili S., Drobeniuc J., Okware S., Downing R., Tappero J.W., Bakamutumaho B., Teo C.G., Ward J.W., Holmberg S.D., Hu D.J. Hepatitis E epidemic, Uganda. Emerg. Infect. Dis. 2010, 16(1):126-129.
20. Tsarev S.A., Tsareva T.S., Emerson S.U., Govindarajan S., Shapiro M., Gerin J.L., Purcell R.H. Recombinant vaccien against hepatitis E: dose response and protection against heterologous challenge. Vaccine 1997, 15(17-18):1834-1838.
21. Worm H.C., van der Poel H.M., Brandstätter G. Hepatitis E: an overview. Microbes Infect. 2002, 4:657-666.
22. Zhang M., Emerson S.U., Nguyen H., Engle R.E., Govindarajan S., Gerin J.L., Purcell R.H. Immunogenicity and protective efficacy of a vaccine prepared from 53kDa truncated hepatitis E virus capsid protein expressed in insect larvae. Vaccine 2001, 20(5-6):853-857.
23. Zhang J., Liu C., Li R., Li Y., Zheng Y., Li Y., Luo D., Pan B., Nong Y., Ge S.X., Xiong J., Shih J.W., Ng M.H., Xia N. Randomized-controled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 2009, 27:1869-1874.
24. Zhu F.C., Zhang J., Zhang X.F., Zhou C., Wang Z.Z., Huang S.J., Wang H., Yang C.L., Jiang H.M., Cai J.P., Wang Y.J., Ai X., Hu Y.M., Tang Q., Yao X., Yan Q., Xiang Y.L., Wu T., Li Y.M., Miao J., Ng M.H., Shih J.W.K., Xia N.S. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010, 376:895-902.